{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06229678",
            "orgStudyIdInfo": {
                "id": "STUDY00000012"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01DK107680",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01DK107680"
                }
            ],
            "organization": {
                "fullName": "The University of Texas Health Science Center at San Antonio",
                "class": "OTHER"
            },
            "briefTitle": "Ketones, SGLT2, HFrEF",
            "officialTitle": "Ketones, Muscle Metabolism, and SGLT2 Inhibitors",
            "therapeuticArea": [
                "Endocrinology",
                "Cardiovascular"
            ],
            "study": "ketones-hfref"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-25",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-11-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-03-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-12-18",
            "studyFirstSubmitQcDate": "2024-01-18",
            "studyFirstPostDateStruct": {
                "date": "2024-01-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-13",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "The University of Texas Health Science Center at San Antonio",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The study team will examine the effects of elevated plasma ketone levels following initiation of SGLT2 inhibitor therapy in high-risk type 2 diabetes mellitus (T2DM) individuals with heart failure (HF) with reduced ejection fraction (HFrEF) providing an energy-rich fuel that is taken up with great avidity by the myocardium, to measure change in Left Ventricle diastolic and systolic function",
            "detailedDescription": "The study team will examine the effects of elevated plasma ketones caused by 12-week treatment with an SGLT2i (empagliflozin) treatment in participants with T2DM and HF. The study team will focus on three possible mechanisms of action for these effects and test the following:\n\n(i) Skeletal muscle bioenergetics. Using 31P-MRS, the team will quantify phosphocreatine \\[PCr\\], ATP, inorganic phosphate, phosphodiester, and intracellular pH. With 1H-MRS, and will measure intramyocellular lipid content at rest and ATPmax production after exercise. The team will examine the relationships between phosphorous metabolite concentrations, intramyocellular lipid content, and ATP generation before and after 12 weeks of SGLT2 inhibition.\n\n(ii) LV systolic and diastolic function using cardiac MRI in type 2 diabetic patients with Class II-III NYHA heart failure and reduced EF.\n\n(iii) To examine the contribution of the SGLT2i-induced increase in plasma ketone concentration on myocardial function and myocardial blood flow by inhibiting the rise in plasma ketone concentration with acipimox while continuing empagliflozin.\n\n(iv) Improvements in Patient-Reported Outcomes (PRO). Kansas City Cardiomyopathy Questionnaire ( KCCQ) scoring will be used to evaluate self-reported physical function and well-being. This tool is a well-developed and validated method to obtain patient self-reported parameters of health in adults."
        },
        "conditionsModule": {
            "conditions": [
                "Type2diabetes",
                "Heart Failure With Reduced Ejection Fraction"
            ],
            "keywords": [
                "ketones",
                "cardiovascular benefit"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "A randomized (2:1) placebo controlled double blind study",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "maskingDescription": "Participants, and investigators will be blinded to the randomization",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 71,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Empagliflozin Group",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects will be randomized 2:1 to receive empagliflozin, 25mg/day for 3 months",
                    "interventionNames": [
                        "Drug: Empagliflozin 25 MG Oral Tablet",
                        "Drug: Acipimox 250 Mg Oral Capsule"
                    ]
                },
                {
                    "label": "Placebo group",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Subjects will be randomized to receive the empagliflozin placebo for 3 months",
                    "interventionNames": [
                        "Drug: Placebo",
                        "Drug: Acipimox 250 Mg Oral Capsule"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Empagliflozin 25 MG Oral Tablet",
                    "description": "Empagliflozin 25MG will be administered orally once per day for 3 months",
                    "armGroupLabels": [
                        "Empagliflozin Group"
                    ],
                    "otherNames": [
                        "jardiance"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "The placebo will be administered orally once per day for 3 months",
                    "armGroupLabels": [
                        "Placebo group"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Acipimox 250 Mg Oral Capsule",
                    "description": "subjects will be started on acipimox 250mg every 6 hours for 8 days while on continued empagliflozin/placebo therapy. This will be added at the end of 3 months after they finished baseline studies",
                    "armGroupLabels": [
                        "Empagliflozin Group",
                        "Placebo group"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in Phosphocreatine",
                    "description": "A measure of phosphocreatine change from baseline to study end",
                    "timeFrame": "Baseline to 3 months"
                },
                {
                    "measure": "Change in Adenosine Triphosphate (ATP)",
                    "description": "A measure of ATP change from baseline to study end",
                    "timeFrame": "Baseline to 3 months"
                },
                {
                    "measure": "Change in Inorganic Phosphate",
                    "description": "A measure of inorganic phosphate change from baseline to study end",
                    "timeFrame": "Baseline to 3 months"
                },
                {
                    "measure": "Change in Phosphodiester",
                    "description": "A measure of phosphodiester change from baseline to study end",
                    "timeFrame": "Baseline to 3 months"
                },
                {
                    "measure": "ATPmax production",
                    "description": "Exercise induced ATPmax production change",
                    "timeFrame": "Baseline to 3 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Plasma Beta-hydroxybutyrate (\u03b2-OH-B)",
                    "description": "Change in \u03b2-OH-B with medication",
                    "timeFrame": "baseline to 3 months"
                },
                {
                    "measure": "Acetoacetate concentrations",
                    "description": "Change in acetoacetate concentrations",
                    "timeFrame": "baseline to 3 months"
                },
                {
                    "measure": "6-min walking test",
                    "description": "Change in the distance that can be covered in a 6 minute walk test",
                    "timeFrame": "baseline to 3 months"
                },
                {
                    "measure": "Patient-Reported Outcomes Measure Information System",
                    "description": "By checking KCCQ (Kansas City Cardiomyopathy) scoring: Responses are categorized under 3 sub scales (symptom burden, physical limitation and quality of life) with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The total KCCQ score represents the mean of the three sub scale scores.",
                    "timeFrame": "baseline to 3 months"
                },
                {
                    "measure": "plasma ketone concentration on myocardial function",
                    "description": "To examine the contribution of the SGLT2i-induced increase in plasma ketone concentration on myocardial function by inhibiting the rise in plasma ketone concentration with acipimox while continuing empagliflozin.",
                    "timeFrame": "Baseline to 3months + 8 days"
                },
                {
                    "measure": "plasma ketone concentration on myocardial blood flow",
                    "description": "To examine the contribution of the SGLT2i-induced increase in plasma ketone concentration on myocardial blood flow by inhibiting the rise in plasma ketone concentration with acipimox while continuing empagliflozin.",
                    "timeFrame": "Baseline to 3months + 8 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n* Class II-III New York Heart Association (NYHA) heart failure and reduced ejection fraction (EF) \\<50%\n* Age 18-80 years\n* BMI 23-38 kg/m2\n* Glycated hemoglobin (HbA1c) 5.5-10%\n* Blood Pressure (BP) \u2264 145/85 mmHg\n* Estimated glomerular filtration rate (eGFR) \u226530 ml/min\u20221.73 m2\n* Stable dose of guideline-directed medications for heart failure\n* Stable body weight (\u00b14 pounds) over the last 3 months\n\nExclusion Criteria:\n\n* Subjects treated with an SGLT2 inhibitor, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or pioglitazone\n* Resting heart rate \\>120 bpm\n* Systolic BP\\>180mmHg and/or diastolic BP \\>100mmHg\n* Resting percentage of blood oxygen saturation (SpO2) \\< 85%\n* Physical disability preventing safe performance of the exercise protocol.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Ralph DeFronzo, MD",
                    "role": "CONTACT",
                    "phone": "210-567-6691",
                    "email": "defronzo@uthscsa.edu"
                },
                {
                    "name": "Sivaram Neppala, MD",
                    "role": "CONTACT",
                    "phone": "210-358-7200",
                    "email": "neppalas@uthscsa.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Ralph DeFronzo, MD",
                    "affiliation": "University of Texas Health Science Center San Antonio",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Texas Diabetes Institute - University Health System",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78207",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sivaram Neppala, MD",
                            "role": "CONTACT",
                            "phone": "210-358-7200",
                            "email": "neppalas@uthscsa.edu"
                        },
                        {
                            "name": "Jemema Rajan, MD",
                            "role": "CONTACT",
                            "phone": "210-358-7200",
                            "email": "rajanj@uthscsa.edu"
                        },
                        {
                            "name": "Ralph DeFronzo, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Sivaram Neppala, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Jemema Rajan, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The PI will actively participate in journal clubs and symposia and present abstracts at national meetings, as well as submit manuscripts to top peer-reviewed journals.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP"
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006333",
                    "term": "Heart Failure"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006331",
                    "term": "Heart Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9421",
                    "name": "Heart Failure",
                    "asFound": "Heart Failure",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7119",
                    "name": "Diabetes Mellitus, Type 2",
                    "relevance": "LOW"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "relevance": "LOW"
                },
                {
                    "id": "M9419",
                    "name": "Heart Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000570240",
                    "term": "Empagliflozin"
                },
                {
                    "id": "C000027696",
                    "term": "Acipimox"
                }
            ],
            "ancestors": [
                {
                    "id": "D000077203",
                    "term": "Sodium-Glucose Transporter 2 Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000960",
                    "term": "Hypolipidemic Agents"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000057847",
                    "term": "Lipid Regulating Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1691",
                    "name": "Sodium-Glucose Transporter 2 Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M258082",
                    "name": "Empagliflozin",
                    "asFound": "Continued",
                    "relevance": "HIGH"
                },
                {
                    "id": "M229334",
                    "name": "Acipimox",
                    "asFound": "Mucoperiosteal flap",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4278",
                    "name": "Hypolipidemic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M28883",
                    "name": "Lipid Regulating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Lipd",
                    "name": "Lipid Regulating Agents"
                }
            ]
        }
    },
    "hasResults": false
}